The FOXG1 Research Foundation announced today that Hourinaz Behesti, PhD., Director of Science, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.
Hosted annually by the Biotechnology Innovation Organization (BIO) for over 20 years, the conference is focused on emerging public and private companies, offering a meeting place for institutional investors, industry analysts, and senior biotech executives. The conference draws biotech companies looking to make the connections needed to take their products to the next phase.
Dr. Behesti’s virtual presentation is titled Tapping into Therapeutic Development for Rare CNS Disorders. She will introduce the rare pediatric CNS disorder, FOXG1 syndrome and discuss why FOXG1 is a viable target for biotech investment, including the suite of assets that the FOXG1 Research Foundation has developed and characterized to help accelerate drug development.
Dr. Behesti’s presentation will be hosted on the BIO CEO & Investor Conference event page beginning Friday, February 11, through the event and after for 30 days.
